BRAF and melanoma: Although the therapeutic landscape for advanced melanoma has radically changed in the last decade since the approval of the different ICI regimens and BRAF/MEKi, a significant percentage of patients still do not benefit from these therapies [1,2,3,4,5,6,7,8,9,10,11,12].